| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/EPR.11.46 |
| P698 | PubMed publication ID | 21999832 |
| P50 | author | Harald Mischak | Q37828676 |
| Amaya Albalat | Q56938823 | ||
| P2093 | author name string | William Mullen | |
| P2860 | cites work | The human plasma proteome: history, character, and diagnostic prospects | Q28218148 |
| Chronic kidney disease and mortality risk: a systematic review | Q28243131 | ||
| Human Proteinpedia enables sharing of human protein data | Q28267923 | ||
| Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology | Q28475613 | ||
| Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy | Q28748796 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease | Q30430034 | ||
| Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis | Q30434677 | ||
| Discovery and validation of urinary biomarkers for prostate cancer | Q30438582 | ||
| Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments | Q30438814 | ||
| Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis | Q30439686 | ||
| Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine | Q30985484 | ||
| A matrix-assisted laser desorption/ionization mass spectrometry study of the non-enzymatic glycation products of human globins in diabetes. | Q31135569 | ||
| Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches | Q31153391 | ||
| Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. | Q33195947 | ||
| Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation | Q33241474 | ||
| Proteomic analysis of differential protein expression in atherosclerosis | Q33246067 | ||
| The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins | Q33256124 | ||
| SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer | Q33306300 | ||
| Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study | Q33402528 | ||
| Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm | Q33436829 | ||
| Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria | Q33488868 | ||
| A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance | Q33527211 | ||
| Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit | Q33640986 | ||
| Advances in proximal fluid proteomics for disease biomarker discovery | Q33731966 | ||
| Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection | Q33748511 | ||
| Addressing the challenge of defining valid proteomic biomarkers and classifiers | Q33786157 | ||
| The choroid plexuses and the barriers between the blood and the cerebrospinal fluid | Q33851301 | ||
| Shotgun proteomics identifies proteins specific for acute renal transplant rejection. | Q33903986 | ||
| The Emergence of Translational Epidemiology: From Scientific Discovery to Population Health Impact | Q34082166 | ||
| Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease | Q34129628 | ||
| Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery | Q34400055 | ||
| Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis | Q34503824 | ||
| Higher-energy C-trap dissociation for peptide modification analysis. | Q34667664 | ||
| Comprehensive human urine standards for comparability and standardization in clinical proteome analysis | Q34725022 | ||
| Strategic paths for biomarker qualification | Q34750888 | ||
| Focus on bladder cancer | Q35868630 | ||
| Pathogenetic mechanisms of diabetic nephropathy | Q36153062 | ||
| The changing epidemiology of diabetic microangiopathy in type 1 diabetes. | Q36178419 | ||
| Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury | Q36514244 | ||
| Molecular markers in bladder cancer: a critical appraisal | Q36526271 | ||
| High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. | Q36601069 | ||
| Urinary proteomics in diabetes and CKD | Q36736792 | ||
| Advances in urinary proteome analysis and biomarker discovery | Q36747925 | ||
| Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study | Q36955241 | ||
| Urinary biomarkers in the early diagnosis of acute kidney injury | Q36982595 | ||
| Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future | Q36985811 | ||
| Urinary biomarkers for acute kidney injury: perspectives on translation. | Q37078758 | ||
| Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy | Q37133857 | ||
| The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease | Q37401369 | ||
| Proteomic approaches for discovering biomarkers of diabetic nephropathy. | Q37753489 | ||
| Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application | Q37806433 | ||
| The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy | Q37817254 | ||
| Mass spectrometry in clinical proteomics - from the present to the future. | Q37817258 | ||
| On the development of plasma protein biomarkers | Q37818127 | ||
| CE-MS in biomarker discovery, validation, and clinical application | Q37833587 | ||
| New pathway for qualification of novel methodologies in the European Medicines Agency | Q37871571 | ||
| Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. | Q39655280 | ||
| Super-SILAC mix for quantitative proteomics of human tumor tissue | Q39719028 | ||
| Quantitative top-down proteomics of SILAC labeled human embryonic stem cells. | Q39732696 | ||
| Urinary proteomics for prediction of preeclampsia | Q39797354 | ||
| Proteomic biomarkers in diabetic nephropathy--reality or future promise? | Q39861080 | ||
| Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. | Q40181424 | ||
| Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. | Q40443299 | ||
| Urine proteomics for profiling of human disease using high accuracy mass spectrometry | Q41378863 | ||
| Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine | Q42015560 | ||
| Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals | Q42920025 | ||
| Early detection of acute renal failure by serum cystatin C. | Q45028930 | ||
| Recommendations for biomarker identification and qualification in clinical proteomics | Q45200767 | ||
| Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease | Q46243933 | ||
| Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery | Q46423060 | ||
| Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery | Q46466958 | ||
| Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis | Q46474917 | ||
| Urinary-peptide excretion by patients with and volunteers without diabetes | Q46497462 | ||
| Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit | Q46691207 | ||
| Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases | Q46899149 | ||
| Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes | Q47588320 | ||
| Common sense approaches to urinary biomarker study design | Q47723130 | ||
| Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation | Q47850193 | ||
| Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. | Q51739894 | ||
| Lessons from controversy: ovarian cancer screening and serum proteomics. | Q52973479 | ||
| Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis | Q54975575 | ||
| Establishment of a European Network for Urine and Kidney Proteomics | Q56444962 | ||
| Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients | Q56970703 | ||
| Urinary Proteomic Biomarkers in Coronary Artery Disease | Q56970751 | ||
| Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes | Q57605349 | ||
| Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury | Q57712015 | ||
| Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics | Q57712052 | ||
| Combined Top-Down and Bottom-Up Mass Spectrometric Approach to Characterization of Biomarkers for Renal Disease | Q57712166 | ||
| Detection of Acute Tubulointerstitial Rejection by Proteomic Analysis of Urinary Samples in Renal Transplant Recipients | Q57712171 | ||
| Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy | Q57712178 | ||
| Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use | Q57712198 | ||
| Translational research: Crossing the valley of death | Q59063636 | ||
| Proteomic-Based Identification of Cleaved Urinary beta2-microglobulin as a Potential Marker for Acute Tubular Injury in Renal Allografts | Q59314391 | ||
| Protocol biopsies in renal transplatation | Q59314419 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 615-629 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Expert Review of Proteomics | Q15749465 |
| P1476 | title | Clinical application of urinary proteomics/peptidomics | |
| P478 | volume | 8 |
| Q48686960 | Biomarkers for AAA: Encouraging steps but clinical relevance still to be delivered. |
| Q38340358 | CE-MS-based proteomics in biomarker discovery and clinical application |
| Q38130892 | Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer |
| Q38176934 | Clinical proteomics in obstetrics and neonatology |
| Q36032361 | Current state of the art for enhancing urine biomarker discovery |
| Q39246192 | Current status and advances in quantitative proteomic mass spectrometry. |
| Q54958844 | Dietary Considerations in Autism Spectrum Disorders: The Potential Role of Protein Digestion and Microbial Putrefaction in the Gut-Brain Axis. |
| Q38063574 | Exoproteomics: exploring the world around biological systems |
| Q34140378 | Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population |
| Q38472655 | Mapping and Identification of the Urine Proteome of Prostate Cancer Patients by 2D PAGE/MS. |
| Q37552845 | Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery |
| Q37621867 | Optimization for peptide sample preparation for urine peptidomics |
| Q51094837 | Prediction of Proteases Involved in Peptide Generation. |
| Q28533986 | Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products |
| Q38091336 | Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications |
| Q38184491 | Review of the CE-MS platform as a powerful alternative to conventional couplings in bio-omics and target-based applications |
| Q38217103 | The urinary proteome and peptidome of renal cell carcinoma patients: a comparison of different techniques |
| Q38172265 | Urinary biomarkers of physical activity: candidates and clinical utility. |
| Q92978454 | Urinary peptidomics and bioinformatics for the detection of diabetic kidney disease |
| Q47781932 | Urinary peptidomics in kidney disease and drug research |
| Q38677349 | Urinary proteomics for the study of genetic kidney diseases |
| Q34155959 | Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches. |
Search more.